Life Sciences.

A GAMP 5-aligned validation methodology integrates validation activities directly into the SAP implementation lifecycle. This includes risk-based testing strategies, full traceability matrices, and documentation packages that satisfy FDA, EMA, and other health authority auditors.

Yes. SAP Advanced Track and Trace for Pharmaceuticals (ATTP) alongside S/4HANA delivers end-to-end serialization, aggregation, and verification capabilities required by DSCSA, covering commissioning, packing, shipping, and verification router integration.

SAP Transportation Management and Warehouse Management can be configured with IoT-enabled temperature monitoring, automated excursion alerts, and deviation workflows, ensuring product integrity throughout the supply chain while maintaining full audit trails.

SAP supports clinical supply operations including demand forecasting for trials, depot management, randomization system integration, kit assembly, and returns/destruction processing. These configurations address the unique requirements of clinical trial supply chains that differ significantly from commercial distribution.

A validated S/4HANA implementation for a mid-sized life sciences company typically takes 12 to 18 months, depending on scope complexity. This includes computer system validation activities, which can add 15 to 20 percent to the timeline compared to non-regulated implementations.

Yes. SAP integrates with LIMS, MES, DCS, and other shop floor systems using SAP Integration Suite, MII, and partner middleware. These integrations require validated interfaces to maintain GxP compliance in regulated manufacturing environments.

Computer System Validation (CSV) is the traditional GAMP 5–based approach requiring documented user requirements, functional specs, IQ/OQ/PQ protocols, and full traceability matrices. Computer Software Assurance (CSA) is the FDA’s newer risk-based framework that reduces documentation burden for lower-risk system functions while maintaining rigorous testing for GxP-critical processes. MYGO helps life sciences organizations determine which approach (or hybrid) is appropriate for each SAP module based on its risk classification and regulatory exposure.

DSCSA requires pharmaceutical companies to exchange transaction data at the package level across the entire supply chain. SAP Advanced Track and Trace for Pharmaceuticals (ATTP) provides the serialization, aggregation, and verification capabilities needed for ongoing compliance, including verification router integration for saleable returns. MYGO implements ATTP with integration to packaging lines, warehouse operations in EWM, and trading partner data exchange through SAP Business Network.

Yes, though the configurations are different. Clinical supply chains require randomization system integration, small-batch manufacturing with expiry management, depot-level inventory, and returns/destruction workflows. Commercial supply chains require high-volume batch production, serialization, and multi-channel distribution. MYGO configures SAP to handle both within a single S/4HANA instance using separate organizational structures and process variants, avoiding the cost and complexity of parallel systems.

In GxP-regulated environments, every SAP change (including patches, support packages, and quarterly SuccessFactors releases) requires a validation impact assessment before deployment. MYGO establishes a managed validation lifecycle that includes automated regression testing with Tricentis, change impact analysis workflows, and streamlined re-validation documentation. This enables organizations to stay current with SAP releases without falling behind on compliance.

Medical device companies typically require SAP Quality Management (QM) for lot-based inspection and device history records, SAP Production Planning for discrete and repetitive manufacturing, SAP PM for equipment qualification and calibration management, and SAP EHS for substance compliance. ISO 13485 requirements drive specific configurations around design controls, CAPA workflows, and unique device identification (UDI) tracking that differ from pharmaceutical implementations.